Nanocovax

BIOLOGICAL2 trials

Sponsors

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Conditions

COVID-19SARS-CoV-2 Infection

Phase 1

A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers

Nanogen Pharmaceutical Biotechnology Joint Stock CompanyCOVID-19

Start: 2020-12-10End: 2021-08-10Target: 620Updated: 2020-12-29

Phase 3

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19

CompletedNCT04922788

Nanogen Pharmaceutical Biotechnology Joint Stock CompanyCOVID-19, SARS-CoV-2 Infection

Start: 2021-06-07End: 2022-07-20Updated: 2025-03-27

Related Papers

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.

2022-05-1616 citations